Department of Gynecology and Obstetrics, University Medical Centre Regensburg, Landshuterstraße 65, 93053, Regensburg, Germany.
Bavarian Cancer Registry, Regional Centre Regensburg, Bavarian Health and Food Safety Authority, Regensburg, Germany.
Breast Cancer Res Treat. 2024 Apr;204(3):607-615. doi: 10.1007/s10549-023-07207-4. Epub 2024 Jan 19.
The optimal time to initiation of adjuvant chemotherapy (TTAC) for triple negative breast cancer (TNBC) patients is unclear. This study evaluates the association between TTAC and survival in TNBC patients.
We conducted a retrospective study using data from a cohort of TNBC patients diagnosed between January 1, 2010 to December 31, 2018, registered in the Tumor Centre Regensburg was conducted. Data included demographics, pathology, treatment, recurrence and survival. TTAC was defined as days from primary surgery to first dose of adjuvant chemotherapy. The Kaplan-Meier method was used to evaluate impact of TTAC on overall survival (OS) and 5-year OS.
A total of 245 TNBC patients treated with adjuvant chemotherapy and valid TTAC data were included. Median TTAC was 29 days. The group receiving systemic therapy within 22 to 28 days after surgery had the most favorable outcome, with median OS of 10.2 years. Groups receiving systemic therapy between 29-35 days, 36-42 days, and more than 6 weeks after surgery had significantly decreased median survival, with median OS of 8.3 years, 7.8 years, and 6.9 years, respectively. Patients receiving therapy between 22-28 days had significantly better survival compared to those receiving therapy between 29-35 days (p = 0.043), and patients receiving therapy after 22-28 days also demonstrated significantly better survival compared to those receiving therapy after more than 43 days (p = 0.033).
Timing of adjuvant systemic therapy can influence OS in TNBC patients. Efforts should be made to avoid unnecessary delays in administering chemotherapy to ensure timely initiation of systemic therapy and optimize patient outcomes.
三阴性乳腺癌（TNBC）患者辅助化疗（TTAC）的最佳起始时间尚不清楚。本研究评估了 TTAC 与 TNBC 患者生存的关系。
我们使用 2010 年 1 月 1 日至 2018 年 12 月 31 日期间在雷根斯堡肿瘤中心注册的 TNBC 患者队列的数据进行了回顾性研究。数据包括人口统计学、病理学、治疗、复发和生存情况。TTAC 定义为从原发性手术到第一剂辅助化疗的天数。采用 Kaplan-Meier 法评估 TTAC 对总生存期（OS）和 5 年 OS 的影响。
共纳入 245 例接受辅助化疗和有效 TTAC 数据的 TNBC 患者。TTAC 的中位时间为 29 天。术后 22-28 天内接受系统治疗的患者结局最佳，中位 OS 为 10.2 年。术后 29-35 天、36-42 天和超过 6 周接受系统治疗的患者中位生存时间明显缩短，中位 OS 分别为 8.3 年、7.8 年和 6.9 年。术后 22-28 天接受治疗的患者与术后 29-35 天接受治疗的患者相比，生存明显更好（p=0.043），而术后 22-28 天接受治疗的患者与术后 43 天以上接受治疗的患者相比，生存也明显更好（p=0.033）。
辅助系统治疗的时间可能会影响 TNBC 患者的 OS。应努力避免化疗的不必要延迟，以确保及时开始系统治疗，优化患者的结局。
